Himeji Medical Center

Response to the Letter Regarding “Methodological Considerations in Real‐World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma”

Data supporting the findings of this study are available from the corresponding author upon reasonable request, subject to institutional review board approval and execution of appropriate data sharing agreements.

Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report

ABSTRACT Introduction Squamous cell carcinoma is a rare bladder cancer subtype with poor prognosis in advanced stages. Currently, there is no established systemic therapy, including immune checkpoint inhibitors, for this subtype. Case Presentation A 49‐year‐old man with pure blad...

An intractable case of primary intra-axial central nervous system Rosai–Dorfman disease

Background: Rosai–Dorfman disease (RDD) is a rare histiocytic disorder with a typically benign clinical course. However, isolated involvement of the central nervous system (CNS), particularly in the form of primary intra-axial disease, is exceedingly rare. We report an intractabl...